Mesothelin is Commonly Expressed in Pancreatic Adenocarcinoma but Unrelated to Cancer Aggressiveness. (21st October 2021)

• Record Type: Journal Article
• Authors: Weidemann, Sören; Perez, Daniel; Izbicki, Jakob R.; Neipp, Michael; Mofid, Hamid; Daniels, Thies; Nahrstedt, Ulf; Jacobsen, Frank; Bernreuther, Christian; Simon, Ronald; Steurer, Stefan; Burandt, Eike; Marx, Andreas H.; Krech, Till; Clauditz, Till S.; Jansen, Kristina
• Is Part Of: Cancer investigation. Volume 39:Number 9(2021)
• Page Start: 711
• Page End: 720
• Publication Date: 2021-10-21
• Subjects: Cancer biomarkers -- pancreatic cancer -- immunohistochemistry; Cancer -- Periodicals; Oncology -- Periodicals; Medical Oncology -- Periodicals; Neoplasms -- Periodicals; 616.994
• DOI: 10.1080/07357907.2021.1943747
• Languages: English
• ISSNs: 0735-7907

Abstract

Abstract: Data on Mesothelin (MSLN) expression in human normal and cancerous tissues is controversial. We employed immunohistochemistry (IHC) on a tissue microarray (TMA) from 599 pancreatic cancers and 12 large tissue sections of pancreatitis. MSLN expression was highest in pancreatic adenocarcinomas (89%) and adenocarcinomas of the ampulla Vateri (79%), infrequent in pancreatitis and absent in 6 acinus cell carcinomas and normal pancreas. MSLN expression was unrelated to pathological tumor stage, grade, metastasis, and tumor-infiltrating CD8+ lymphocytes. In conclusion, pancreatic cancer may be ideally suited for putative anti- MSLN therapies, and MSLN may represent a suitable biomarker for pancreatic cancer diagnosis, especially on small biopsies.